BUFFALO, NY — October 6, 2026 — A new research paper was recently published in Volume 18 of Aging, titled “Spatially fractionated mini-GRID radiotherapy differentially modulates radiation-induced senescence in murine glioma and normal cells.”

Dr. Olivier Elemento, the director of the Englander Institute for Precision Medicine at Weill Cornell Medicine, has been awarded an NIH Director's Pioneer Award to build an artificial intelligence (AI) tool to accelerate cancer research, starting with lung cancer.

Dr. Michael Taylor, a Texas Children’s pediatric neurosurgeon and researcher whose work has advanced understanding of childhood brain tumors, is among the first four grantees to receive a Texans Conquer Cancer Award from the Cancer Prevention and Research Institute of Texas (CPRIT).

Results from ECOG-ACRIN’s CompassHER2-pCR trial identify clinical and molecular predictors of pathologic complete response (pCR) after 12 weeks of THP, a less intensive neoadjuvant regimen combining one chemotherapy drug with two HER2-targeted drugs. It is the largest prospective trial of this approach in stage II-IIIA HER2+ breast cancer. Follow-up is ongoing to assess 3-year recurrence-free survival among patients who had a pCR. Published in JCO, the findings will be featured in a podcast.

Our birthdays tell us how long we have lived, but not necessarily how our bodies are aging. Biological age reflects the condition and function of our cells and tissues, shaped by genetics, lifestyle, environment, and disease. In people with chronic conditions such as cancer, kidney disease, and heart disease, researchers have observed signs of aging that appear earlier than expected for a person’s age. This is known as accelerated biological aging.

PSMA PET/CT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men whose MRI findings are negative or inconclusive yet have persistent clinical risk factors. According to new research published in the September issue of The Journal of Nuclear Medicine, combining the two biopsy approaches is even more effective, nearly doubling the detection rate. This strategy may help physicians identify clinically significant cancers that would otherwise be difficult to detect, while potentially avoiding unnecessary procedures in appropriately selected patients.